|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print May 22, 2002
Am J Physiol Cell Physiol, 10.1152/ajpcell.00046.2002
Submitted on January 29, 2002
Accepted on May 17, 2002
1 Internal Medicine, City Hospital, Adria, Rovigo, Italy
2 Biomedical Sciences, CNR Unit Muscle Biology and Physiopathology, Padova, Padova, Italy
3 Cardiovascular Pathology, University of Padova, Padova, Padova, Italy
4 Experimental Oncology, National Cancer Institute, Napoli, Napoli, Italy
5 Scientific Department, Sigma Tau, Roma, Roma, Italy
* To whom correspondence should be addressed. E-mail: ldl{at}civ.bio.unipd.it.
Skeletal muscle in congestive heart failure is responsible for increased fatigability, decreased exercise capacity and endurance. A specific myopathy with increased expression of fast-type myosins, myocyte atrophy, secondary to myocyte apoptosis triggered by high levels of circulating TNF
has been described. In an animal model of heart failure, the monocrotaline-treated rat, we have observed an increase of apoptotic skeletal muscle nuclei. Proapoptotic agents, caspases 3 and 9, were increased, as well as serum levels of TNF
and its second messenger sphingosine. Treatment of rats with L-carnitine, known for its protective effect on muscle metabolism injuries, was found to inhibit caspases, to decrease the levels of TNF
and sphingosine as well the number of apoptotic myonuclei. Staurosporine was used in in vitro experiments, to induce apoptosis in skeletal muscle cells in culture. When increasing concentrations of L-carnitine were applied to skeletal muscle cells, before staurosporine treatment, we observed a dose-dependent reduction in apoptosis. These findings show that L-carnitine can prevent apoptosis of skeletal muscles cells and can have a role in the treatment of congestive heart failure-associated myopathy.
This article has been cited by other articles:
![]() |
L. A Calo, P. A Davis, E. Pagnin, L. Bertipaglia, A. Naso, A. Piccoli, R. Corradini, M. Spinello, V. Savica, and L. D. Libera Carnitine-mediated improved response to erythropoietin involves induction of haem oxygenase-1: studies in humans and in an animal model Nephrol. Dial. Transplant., March 1, 2008; 23(3): 890 - 895. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Schreiber Levocarnitine and Dialysis: A Review Nutr Clin Pract, April 1, 2005; 20(2): 218 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ventura-Clapier, A. Garnier, and V. Veksler Energy metabolism in heart failure J. Physiol., February 15, 2004; 555(1): 1 - 13. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Dalla Libera, B. Ravara, M. Volterrani, V. Gobbo, M. Della Barbera, A. Angelini, D. D. Betto, E. Germinario, and G. Vescovo Beneficial effects of GH/IGF-1 on skeletal muscle atrophy and function in experimental heart failure Am J Physiol Cell Physiol, January 1, 2004; 286(1): C138 - C144. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Selman and C. Leeuwenburgh The role of Id2 and apoptosis during skeletal muscle remodeling Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2003; 284(2): R538 - R539. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |